Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX/TEZ/IVA in children aged 6 to 11 years with cystic fibrosis and F508del/minimal function genotype
NL-OMON49334Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cystic fibrosis (CF) comparing ELX/TEZ/IVA with Placebo (2 arms). Primary endpoint: Absolute change in lung clearance index2.5 from baseline through Week 24. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON49334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49334.